Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORAL STRATEGY: Tofacitinib vs Adalimumab in Rheumatoid Arthritis
NCT02187055Phase 4Completed
- Sponsor
- Pfizer
- Start
- Aug 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 4, randomised, double-blind trial of tofacitinib oral solution in rheumatoid arthritis (RA) (3 arms), sponsored by Pfizer. Primary endpoint: American College of Rheumatology Criteria 50% Improvement at 6 months. Started Aug 2014; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02187055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02187055.